Cargando…

Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment

Alzheimer disease (AD) is a devastating disease and a global health problem, and current treatments are only symptomatic. A wealth of clinical studies support that the disease starts to develop decades before the first symptoms appear, emphasizing the importance of studying early changes for improvi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schedin‐Weiss, Sophia, Gaunitz, Stefan, Sui, Ping, Chen, Qiushi, Haslam, Stuart M., Blennow, Kaj, Winblad, Bengt, Dell, Anne, Tjernberg, Lars O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496940/ https://www.ncbi.nlm.nih.gov/pubmed/31889402 http://dx.doi.org/10.1111/febs.15197

Ejemplares similares

What Can N-glycomics and N-glycoproteomics of Cerebrospinal Fluid Tell Us about Alzheimer Disease?
por: Gaunitz, Stefan, et al.
Publicado: (2021)

The N‐glycan profile in cortex and hippocampus is altered in Alzheimer disease
por: Gaunitz, Stefan, et al.
Publicado: (2020)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease
por: Degerman Gunnarsson, Malin, et al.
Publicado: (2016)

A Super-Resolved View of the Alzheimer’s Disease-Related Amyloidogenic Pathway in Hippocampal Neurons
por: Yu, Yang, et al.
Publicado: (2021)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2020)

Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke
por: De Vos, Ann, et al.
Publicado: (2017)

Monoamine oxidase B is associated with γ-secretase in cultured neurons and in brain
por: Weiss, Sophia Schedin, et al.
Publicado: (2013)

Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations
por: Brown, Jessica, et al.
Publicado: (2023)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

The nonlinear relationship between cerebrospinal fluid Aβ(42) and tau in preclinical Alzheimer’s disease
por: de Leon, Mony J., et al.
Publicado: (2018)

Super-resolution microscopy reveals γ-secretase at both sides of the neuronal synapse
por: Schedin-Weiss, Sophia, et al.
Publicado: (2016)

Live Cell FRET Imaging Reveals Amyloid β-Peptide Oligomerization in Hippocampal Neurons
por: Gao, Yang, et al.
Publicado: (2021)

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
por: Cicognola, Claudia, et al.
Publicado: (2018)

Tau as a fluid biomarker of concussion and neurodegeneration
por: Hossain, Iftakher, et al.
Publicado: (2022)

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein
por: Zettergren, Anna, et al.
Publicado: (2019)

Neuronal Aβ42 is enriched in small vesicles at the presynaptic side of synapses
por: Yu, Yang, et al.
Publicado: (2018)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Microdissected Pyramidal Cell Proteomics of Alzheimer Brain Reveals Alterations in Creatine Kinase B-Type, 14-3-3-γ, and Heat Shock Cognate 71
por: Sandebring-Matton, Anna, et al.
Publicado: (2021)

The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals
por: Bruno, Davide, et al.
Publicado: (2015)

Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease
por: Kramberger, Milica Gregoric, et al.
Publicado: (2012)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Genome-Wide Epistasis Study of Cerebrospinal Fluid Hyperphosphorylated Tau in ADNI Cohort
por: Chen, Dandan, et al.
Publicado: (2023)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS)
por: Saunders, Tyler S., et al.
Publicado: (2022)

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest
por: Foiani, Martha S, et al.
Publicado: (2019)

Changes in dementia diagnoses in Sweden during the COVID-19 pandemic
por: Axenhus, Michael, et al.
Publicado: (2022)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
por: Erickson, Pontus, et al.
Publicado: (2023)

Visualizing Active Enzyme Complexes Using a Photoreactive Inhibitor for Proximity Ligation – Application on γ-Secretase
por: Schedin-Weiss, Sophia, et al.
Publicado: (2013)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

Proteomics Time-Course Study of App Knock-In Mice Reveals Novel Presymptomatic Aβ(42)-Induced Pathways to Alzheimer’s Disease Pathology
por: Schedin-Weiss, Sophia, et al.
Publicado: (2020)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_l6sd196q8ibiobfaa1m3k1a2ut